

FILE 'REGISTRY' ENTERED AT 16:05:26 ON 13 MAY 2009

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 20 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:06:42 ON 13 MAY 2009

L4 8 S L3

FILE 'HOME' ENTERED AT 16:05:05 ON 13 MAY 2009

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.22	0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:05:26 ON 13 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2009 HIGHEST RN 1146247-90-6
DICTIONARY FILE UPDATES: 12 MAY 2009 HIGHEST RN 1146247-90-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10529431generic.str



chain nodes :

21 22 23 29 36 37 38 39 40 41 42

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 24 25 26
27 28 30 31 32 33 34 35

chain bonds :

1-21 4-38 4-39 7-40 7-41 8-42 9-15 21-22 21-23 23-24 25-37 27-36 28-29
29-30

ring bonds :

1-2 1-7 2-3 2-11 3-4 3-14 4-5 5-6 5-8 6-7 6-10 8-9 9-10 11-12 12-13
13-14 15-16 15-20 16-17 17-18 18-19 19-20 24-25 24-28 25-26 26-27 27-28
30-31 30-35

31-32 32-33 33-34 34-35
 exact/norm bonds :
 1-2 1-7 1-21 3-4 4-5 5-6 5-8 6-7 6-10 8-9 9-10 21-22 24-25 24-28 25-26
 26-27 27-28
 exact bonds :
 4-38 4-39 7-40 7-41 8-42 9-15 21-23 23-24 25-37 27-36 28-29 29-30
 normalized bonds :
 2-3 2-11 3-14 11-12 12-13 13-14 15-16 15-20 16-17 17-18 18-19 19-20
 30-31
 30-35 31-32 32-33 33-34 34-35

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 21:CLASS
 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS 30:Atom
 31:Atom 32:Atom
 33:Atom 34:Atom 35:Atom 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
 41:CLASS 42:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 16:06:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 68 TO 532

PROJECTED ANSWERS: 3 TO 163


L2 3 SEA SSS SAM L1

=> d l2 scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzonitrile, 4-[[5-[2-[8-bromo-2-(2-methoxyphenyl)-5H-imidazo[2,1-c][1,4]benzodiazepin-10(11H)-yl]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-, hydrochloride (1:2)


MF C31 H25 Br N6 O2 . 2 Cl H



● 2 HCl


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzonitrile, 4-[[5-[2-[6-fluoro-2-(2-methoxyphenyl)-5H-imidazo[2,1-c][1,4]benzodiazepin-10(11H)-yl]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-2-methoxy-
 MF C32 H27 F N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Benzonitrile, 4-[[5-[2-[2-(2-bromophenyl)-6-fluoro-5H-imidazo[2,1-c][1,4]benzodiazepin-10(11H)-yl]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-2-methoxy-
 MF C31 H24 Br F N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
 FULL SEARCH INITIATED 16:06:36 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 340 TO ITERATE

100.0% PROCESSED 340 ITERATIONS 20 ANSWERS
 SEARCH TIME: 00.00.01

L3 20 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	186.36	186.58

FILE 'HCAPLUS' ENTERED AT 16:06:42 ON 13 MAY 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 May 2009 VOL 150 ISS 20

FILE LAST UPDATED: 12 May 2009 (20090512/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAPLUS now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3


L4 8 L3

=> d l4 1-8 ti abs bib

L4 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related
compounds as prenyl transferase inhibitors.

GI



AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z
= O, bond, etc.; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl,
triazolyl, etc.; R3 = H, (substituted) alkyl, alkenyl, etc.; R4, R5 = H,
(substituted) alkyl, cycloalkyl, etc.; R6 = H, (substituted) alkyl,
alkenyl, etc.; R7 = H, :O, :S, (substituted) alkyl, etc.; W = null, C],
were prepared as prenyl transferase inhibitors (no data). Thus,
1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-
(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over
Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine.
This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-
methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

AN 2008:490553 HCAPLUS <<LOGINID:20090513>>

DN 148:449668

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related
compounds as prenyl transferase inhibitors.

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe de Conseils de Recherches et d'Applications Scientifiques, S.a.S.,
Fr.

SO U.S., 34pp., Cont.-in-part of U.S. Ser. No. 224428.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

PATENT NO.

KIND


DATE

APPLICATION NO.

DATE

PI	US 7361656	B2	20080422	US 2006-353518	20060214
	US 20060142275	A1	20060629		
	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 7084135	B1	20060801	US 2001-868356	20010810
	US 20080176835	A1	20080724	US 2007-929118	20071030
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	B2	19981231		
	WO 1999-US31302	W	19991230		
	US 2001-868356	A1	20010810		
	EP 1999-968984	A3	19991230		
	US 2006-353518	A3	20060214		
OS	MARPAT 148:449668				
RE.CNT	7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L4 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS ON STN
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors
GI



AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over

Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine.
This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.
Pharmaceutical composition comprising the compound I and methods of treating cancer and other diseases are disclosed.

AN 2006:759518 HCAPLUS <<LOGINID::20090513>>
DN 145:188920

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe De Conseils De Recherches Et D'Applications Scientifiques, Sas, Fr.

SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 224,428, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7084135	B1	20060801	US 2001-868356	20010810
	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 7361656	B2	20080422	US 2006-353518	20060214
	US 20060142275	A1	20060629		
	US 20080176835	A1	20080724	US 2007-929118	20071030
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	B2	19981231		
	WO 1999-US31302	W	19991230		
	EP 1999-968984	A3	19991230		
	US 2001-868356	A1	20010810		
	US 2006-353518	A3	20060214		


OS MARPAT 145:188920

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

GI



AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 HCAPLUS <<LOGINID:20090513>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
	WO 2004028541	A3	20040701		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003274565	A1	20040419	AU 2003-274565	20030929
	EP 1542691	A2	20050622	EP 2003-758540	20030929
	EP 1542691	B1	20090107		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006500421	T	20060105	JP 2004-539385	20030929
	AT 419852	T	20090115	AT 2003-758540	20030929
	ES 2316811	T3	20090416	ES 2003-758540	20030929
	US 20060166907	A1	20060727	US 2005-529431	20050325
	US 20080161253	A1	20080703	US 2008-74729	20080306
PRAI	US 2002-414103P	P	20020927		
	WO 2003-IB4922	W	20030929		
	US 2005-529431	A1	20050325		

OS MARPAT 140:315043

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
 AB Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much more sensitive to chemotherapy than other head and neck carcinomas. Spectacular regressions are frequently observed after induction chemotherapy. However, these favorable responses are difficult to predict and often of short duration. So far there have been only few expts. to investigate the mechanisms which underline the cytotoxic effects of anti-neoplastic drugs against NPC cells. In addition, these studies were performed almost entirely on EBV-neg. cell lines therefore not truly representative of NPC cells. For the first time, we have used two EBV-pos. NPC tumor lines derived from a North African (C15) and a Chinese (C666-1) patient as in vitro targets for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser extent cis-platinum efficiently inhibited NPC cell proliferation at clin. relevant concns., but all three agents failed to induce apoptosis. However, massive apoptosis of C15 cells was achieved when doxorubicin (1 µM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5 µM). Moreover, this apoptotic process was associated with a caspase-dependent early cleavage of the TNF-receptor associated factor 1 (TRAF-1) mol., a signaling adaptor which is specifically expressed in latently EBV-infected cells. TRAF-1 cleavage might become a useful indicator of chemo-induced apoptosis in EBV-associated NPCs.
 AN 2003:28618 HCAPLUS <<LOGINID::20090513>>
 DN 139:46523
 TI Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor
 AU Vicat, Jean-Michel; Ardila-Osorio, Hector; Khabir, Abdelmajid; Brezak, Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jldi, Rachid; Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.; Busson, Pierre
 CS UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.
 SO Biochemical Pharmacology (2003), 65(3), 423-433
 CODEN: BCPCA6; ISSN: 0006-2952
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns a product comprising at least mikanolide (I), dihydromikanolide or an analog, e.g., II [R1 = H, SR4, NR4R5; R2 = SR6, NR6R7; R3 = OH, O-acyl, O-silyl, O-carbamyl; R4, R6 = alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R5, R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R4R5 = 5- to 7-membered N-containing ring] and III, or their pharmaceutically acceptable salts, combined with at least one other

anticancer agent for simultaneous, sep. or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analog thereof is combined with enzymic inhibitors such as G heterotrimeric protein inhibitors, IV [X = R22; Y = R18; XY = 6-membered ring, CHR18CHR19; R11 = H, lower alkyl, alkylthio; R12, R13 = H, lower alkyl; R14 = O, H2; R5 = H, lower alkyl, (cycloalkyl)alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclialkyl; R16, R17 = H, CONHCHR13CO2R14, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclialkyl; R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclialkyl; R18R19 = aryl or heterocycl ring; R20, R21 = H, aryl, heterocyclyl, alkyl, arylalkyl, heterocyclialkyl; R22 = NR9, S, O; R23 = ; R24 = H, lower alkyl, V (R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclialkyl; R18R19 = aryl or heterocycl ring) or VI (R22 = NR9, S, O), or alkylating agents such as cis-platin. Thus, VII was prepared from mikanolide. VII was tested for cell proliferation inhibition activity [only 34% of cells lived when combined with VIII·HCl (vs. human colon cancer HT-29 cells)].

AN 2002:927175 HCAPLUS <<LOGINID:20090513>>

DN 138:14131

TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment

IN Prevost, Gregoire; Coulomb, Helene; Lavergne, Olivier; Lanco, Christophe; Teng, Beng-Poon

PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096348	A2	20021205	WO 2002-FR1800	20020529
	WO 2002096348	A3	20040506		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	FR 2825278	A1	20021206	FR 2001-7104	20010530
	CA 2448528	A1	20021205	CA 2002-2448528	20020529
	AU 2002313087	A1	20021209	AU 2002-313087	20020529
	EP 1438039	A2	20040721	EP 2002-738284	20020529
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2004533456	T	20041104	JP 2002-592861	20020529
	CN 1691941	A	20051102	CN 2002-812592	20020529
	HU 2004000153	A2	20070730	HU 2004-153	20020529
	US 20040138245	A1	20040715	US 2003-478387	20031211
PRAI	WO 2001-7104	A	20010530		
	WO 2002-FR1800	W	20020529		

OS MARPAT 138:14131

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Product inhibiting heterotrimeric G protein signal transduction combined
 with another anticancer agent for therapeutic use in cancer treatment
 AB The invention provides a product inhibiting heterotrimeric G protein
 signal transduction combined with another anticancer agent, in particular
 a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous,
 sep., or prolonged therapeutic use in cancer treatment.
 AN 2001:359845 HCAPLUS <<LOGINID:20090513>>
 DN 134:361346
 TI Product inhibiting heterotrimeric G protein signal transduction combined
 with another anticancer agent for therapeutic use in cancer treatment
 IN Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas; Morgan, Barry
 PA Societe de Conseils de Recherches et d'Applications Scientifiques
 (S.C.R.A.S.), Fr.
 SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034203	A1	20010517	WO 2000-FR3098	200001108
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2800616	A1	20010511	FR 1999-14037	19991109
	FR 2800616	B1	20020118		
	FR 2803524	A1	20010713	FR 2000-104	20000106
	FR 2803524	B1	20020419		
	CA 2390317	A1	20010517	CA 2000-2390317	20001108
	EP 1233787	A1	20020828	EP 2000-976116	20001108
	EP 1233787	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2002003241	A2	20030228	HU 2002-3241	20001108
	HU 2002003241	A3	20060728		
	JP 2003513940	T	20030415	JP 2001-536200	20001108
	EP 1430934	A1	20040623	EP 2004-75491	20001108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 284224	T	20041215	AT 2000-976116	20001108
	ES 2234692	T3	20050701	ES 2000-976116	20001108
	RU 2298417	C2	20070510	RU 2002-115262	20001108
	US 7034024	B1	20060425	US 2002-129569	20020621
	US 20060074078	A1	20060406	US 2005-272304	20051110
PRAI	FR 1999-14037	A	19991109		
	FR 2000-104	A	20000106		
	EP 2000-976116	A3	20001108		
	WO 2000-FR3098	W	20001108		
	US 2002-129569	A3	20020621		

OS MARPAT 134:361346

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228

AB This work reports a novel farnesyltransferase inhibitor, BIM-46228, which gave: (1) specific inhibition of purified human farnesyltransferase enzyme, (2) inhibition of proliferation of a broad spectrum of human tumor cell lines in vitro, (3) inhibition of the growth of human tumor xenografts in athymic nude mice treated orally and (4) combination of its activity with chemotherapy (paclitaxel) or radiotherapy in vitro.

AN 2001:128354 HCAPLUS <<LOGINID:20090513>>

DN 135:174767

TI Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228

AU Prevost, Gregoire P.; Pradines, Anne; Brezak, Marie-Christine; Lonchampt, Marie-Odile; Viossat, Isabelle; Ader, Isabelle; Toulas, Christine; Kasprzyk, Philip; Gordon, Thomas; Favre, Gilles; Morgan, Barry

CS Institut Henri Beaufour, Les Ulis, F-91966, Fr.

SO International Journal of Cancer (2001), 91(5), 718-722

CODEN: IJCNAN; ISSN: 0020-7136

PB Wiley-Liss, Inc.

DT Journal

LA English


RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS ON STN

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.

GI



AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, Cl, were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazo-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

AN 2000:457071 HCAPLUS <<LOGINID:20090513>>

DN 133:89553

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related
 compounds as prenyl transferase inhibitors.
 IN Gordon, Thomas B.; Morgan, Barry A.
 PA Societe de Conseils de Recherches et d'Applications Scientifiques S.A.,
 Fr.
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2356756	A1	20000706	CA 1999-2356756	19991230
	EP 1140942	A2	20011010	EP 1999-968984	19991230
	EP 1140942	B1	20040310		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	HU 2001004708	A2	20020429	HU 2001-4708	19991230
	HU 2001004708	A3	20040528		
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
	AT 261447	T	20040315	AT 1999-968984	19991230
	ES 2215420	T3	20041001	ES 1999-968984	19991230
	RU 2241712	C2	20041210	RU 2001-121317	19991230
	NO 2001003281	A	20010829	NO 2001-3281	20010629
	NO 321057	B1	20060306		
	US 7084135	B1	20060801	US 2001-868356	20010810
	US 7361656	B2	20080422	US 2006-353518	20060214
	US 20060142275	A1	20060629		
	US 20080176835	A1	20080724	US 2007-929118	20071030
PRAI	US 1998-114301P	P	19981231		
	US 1998-224428	A1	19981231		
	EP 1999-968984	A3	19991230		
	WO 1999-US31302	W	19991230		
	US 2001-868356	A1	20010810		
	US 2006-353518	A3	20060214		

OS MARPAT 133:89553
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT